SALT LAKE CITY--(BUSINESS WIRE)-- BSD Medical Corporation (NASDAQ:BSDM) (www.bsdmedical.com) today announced publication of an issue of the official journal of the German Cancer Society, Der Onkologe, that is dedicated to the current role of hyperthermia in cancer treatment. The publication focuses on all aspects of the role of hyperthermia in clinical oncology and emphasizes the benefits of hyperthermia for the treatment of recurrent breast cancer, advanced rectal and cervical cancer, and anal cancer.
One article published in Der Onkologe advocates the use of hyperthermia in the clinical practice of oncology, based on a review of twenty-one randomized clinical studies. The article, “The role of hyperthermia in current radiation oncology”, (November 2010: DOI 10.1007/s00761-010-1898-3) was authored by Drs. OJ Ott, M Schmidt, R Sauer, R Fietkau, and V Heinrich, five leading oncology researchers from the University Medical Schools of Erlangen and Tuebingen in Germany. The researchers reported that a significant number of randomized studies have demonstrated that the addition of hyperthermia to radiation can improve response rate, local control and overall survival without a significant increase in toxicity, which makes hyperthermia a very attractive radiation sensitizer for radiation oncologists.
The researchers stated, “The additional use of local and regional hyperthermia techniques during a series of radio- or radiochemotherapy may improve relevant clinical endpoints such as response rate, local control, and overall survival. Several randomized clinical trials documented the additional benefits of using hyperthermia, especially for patients with locally recurrent breast cancer after mastectomy, locally advanced primary rectal and cervical cancer as well as for patients with anal cancer. The big advantage of additional hyperthermia is the unspecific radio- and chemosensitizing effect which is effective in various localized tumor entities. It is no longer the question of whether hyperthermia is an effective part of the oncological treatment armamentarium. Today, the question is which patients treated by which multimodal oncological standard approach benefit most from additional local and regional hyperthermia treatments.”
The article reviewed a total of 18 randomized studies comparing hyperthermia and radiation therapy to radiation therapy alone. Six randomized studies evaluated the efficacy of hyperthermia in 306 patients with breast carcinoma. Six randomized studies evaluated the efficacy of hyperthermia in 520 patients with locally advanced rectal carcinoma. Six randomized studies evaluated the efficacy of hyperthermia in 498 patients with cervical carcinoma. A review of these studies demonstrated that the addition of hyperthermia to radiation therapy can improve response rate, local control and overall survival without a significant increase in toxicity.
The researchers also reviewed three randomized studies that evaluated the addition of hyperthermia to combined radiation therapy and chemotherapy (radiochemotherapy) for the treatment of rectal cancer, anal cancer, and esophageal cancer. The authors stressed that these three studies emphasized the ability of hyperthermia to increase the efficacy of both radiation and chemotherapy for certain tumors.
The medical researchers concluded that hyperthermia can enhance the efficacy of radiation therapy and radiochemotherapy and that hyperthermia treatment should be considered for the treatment of cancer patients as part of the clinical practice of oncology, particularly in situations where the outlook for success is limited with standard therapy.
About Der Onkologe
Der Onkologe, the official journal of the German Cancer Society, is a medical publication that focuses on relevant issues concerning the diagnosis and therapy of oncological diseases. This interdisciplinary journal addresses the needs of researchers and doctors working in the field of oncology. The core of each issue consists of comprehensive reviews on a specific topical issue, with a focus on providing evidence-based information on therapy relevant for daily practice. After the topics are selected by an independent editorial board, established experts prepare the articles for each issue.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.
Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.
BSD Medical Corporation
Dennis Gauger, 801-972-5555
KEYWORDS: United States Europe North America Germany Utah
INDUSTRY KEYWORDS: Health Biotechnology Hospitals Medical Devices Oncology Radiology General Health